SCHEMBL280133

SCHEMBL280133

Cc1ccc(C(=O)CN(c2nccs2)C2CCNCC2)s1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
TRPM8 Q7Z2W7 1/20 0.35
ADORA2A P29274 3/20 0.34
ADORA2B P29275 2/20 0.34
ALDH1A1 P00352 3/20 0.34
GLA P06280 1/20 0.34
TSHR P16473 1/20 0.34
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
NMT1 P30419 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CACNA2D1 P54289 1/20 0.32
GAA P10253 1/20 0.32
DAO P14920 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12806984 0.74 NMT1 (0.43) TRPM8SLC6A2SLC6A4SLC6A3NMT1
SCHEMBL279866 0.69 MAOA (0.48) NPC1RAB9AALDH1A1L3MBTL1DAO
SCHEMBL280207 0.69 NPC1 (0.37) NPC1RAB9AALDH1A1GLATSHR
SCHEMBL7657929 0.68 SLC6A2 (0.48) TRPM8SLC6A2SLC6A4SLC6A3
SCHEMBL12806995 0.67 NMT1 (0.46) TRPM8SLC6A2SLC6A4SLC6A3NMT1
SCHEMBL27588989 0.67 TRPM8 (0.44) TRPM8ALDH1A1TSHRSLC6A2SLC6A4
SCHEMBL279864 0.66 ALDH1A1 (0.46) NPC1RAB9AALDH1A1L3MBTL1DAO
SCHEMBL3064062 0.64 TRPM8 (0.36) TRPM8ALDH1A1TSHRNMT1
SCHEMBL12807032 0.63 CHRM2 (0.44) TRPM8SLC6A2SLC6A4SLC6A3NMT1
SCHEMBL13326824 0.63 CHRM2 (0.44) TRPM8SLC6A2SLC6A4SLC6A3NMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL NPC1 3107/4885RAB9A 2458/4885TRPM8 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.